Suppr超能文献

抗肉毒神经毒素 A 中和抗体的制备与鉴定。

Production and characterization of a neutralizing antibody against botulinum neurotoxin A.

机构信息

Laboratory of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, PR China.

Laboratory of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, PR China; College of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, PR China.

出版信息

J Immunol Methods. 2020 Dec;487:112871. doi: 10.1016/j.jim.2020.112871. Epub 2020 Sep 30.

Abstract

As a category A toxic, the botulinum toxin(BoNT) is responsible for human botulism with an estimated lethal dose of 1 ng/kg which greatly increases the potential risk of use as bioweapons. Therefore, the development of anti-BoNT antibodies is urgent. In this paper, the H domain of BoNT/A was purified and immunized with Balb/c mice. Monoclonal antibodies were screened against BoNT/A from 55 stable positive hybridoma cell lines, and one with the strongest neutralizing activity, designated as ML06, was subcloned, sequenced, and classified as IgG1(κ) subclass. The mouse protection assays showed that ML06 can neutralize the toxin of BoNT/A effectively both in vitro and in vivo, in a dose-dependent manner. The therapeutic assays showed that only 20% of mice injected with 4 LD BoNT/A can survive another injection of ML06 after 4 h. The prophylaxis assays showed the residual ML06 from mice injected with ML06 two weeks ago can protect mice against 4 LD BoNT/A challenge completely. Collectively, our results indicated that ML06 served as a good candidate for further development of immune therapeutics for BoNT/A.

摘要

作为一种 A 类毒素,肉毒梭菌毒素(BoNT)是人类肉毒中毒的罪魁祸首,估计其致死剂量为 1ng/kg,这大大增加了将其用作生物武器的潜在风险。因此,开发抗 BoNT 抗体迫在眉睫。本文对 BoNT/A 的 H 结构域进行了纯化,并对 Balb/c 小鼠进行了免疫。从 55 株稳定阳性杂交瘤细胞系中筛选出针对 BoNT/A 的单克隆抗体,其中一种具有最强中和活性的抗体被命名为 ML06,并进行了亚克隆、测序和分类为 IgG1(κ)亚类。小鼠保护实验表明,ML06 可以在体外和体内以剂量依赖的方式有效中和 BoNT/A 的毒素。治疗实验表明,在 4 小时后再次注射 ML06,仅 4LD BoNT/A 注射的 20%的小鼠可以存活。预防实验表明,两周前注射 ML06 的小鼠体内残留的 ML06 可以完全保护小鼠免受 4LD BoNT/A 攻击。总之,我们的结果表明,ML06 是进一步开发 BoNT/A 免疫治疗药物的良好候选物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验